The expressions of CD163 and α-SMA are independent prognostic factors for the overall survival and progression-free survival; failure risk groups based on expression levels of CD163 and α-SMA are independent predictors for the survival of patients with NPC 124. This evidence concerns the gene ACTA1 and nasopharyngeal carcinoma.